No Data
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Express News | US weight loss drug concept stocks rose across the board, with Viking Therapeutics up more than 5%, Altimmune and Eli Lilly and Co up more than 3%, Sorrento Biologicals and Novo-Nordisk A/S up more than 2%. Previously, US President Biden proposed medical
Amgen (AMGN.US) releases mid-term data for weight loss therapy MariTide, with weight loss results comparable to Novartis.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide has achieved significant results in Phase 2 trials.
Altimmune to Participate at Two Upcoming Investor Conferences
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Executive Reshuffles: TWO, CYBR, PFG and ALT